Icahn confederate could profit off a seat on Forest board

Carl Icahn accuses Forest Laboratories ($FRX) of bad governance. But is Icahn calling the kettle black? Experts are raising questions about his incentive plan for one nominee to Forest Labs' board. Icahn promised Eric Ende, a former biotech analyst and close associate, a cut of the profits if Forest's stock increases past $47.50 per share. As Reuters reports, Ende's 1% share of those profits would amount to $659,000, if Icahn were to sell his Forest stock at a $50-per-share price. Report

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.